March 2018
Germany

 

2017 Speakers

Expand/Collapse

Floris van Delft
CSO
Synaffix

Floris van Delft (PhD) is a founder and the Chief Scientific Officer of SynAffix. Previously, Floris held a position as associate professor at the Radboud University Nijmegen, with special focus on click chemistry and protein conjugation technologies, before shifting his professional activities full-time from academic research to SynAffix in 2013. Earlier academic appointments involved a postdoctoral research position at the Scripps Research Institute (San Diego, USA) and an assistant professorship at the University of Amsterdam. Floris received his MSc and PhD (cum laude) from Leiden University (the Netherlands) in carbohydrate chemistry and stereoselective synthesis. He has authored >120 peer-reviewed publications and 14 patents.  

Day One

Tuesday 21st February, 2017

17:00 | Better than Cysteine-Engineered ADCs Too…

Matthew Bird
Team Leader
Abzena

Matthew Bird is Team Leader of Abzena’s bioconjugation group specialising in the development of Abzena’s ThioBridge™ ADC linker technology, he has worked in Abzena’s bioconjugation group since 2010 following his PhD from University of Reading and work as a process chemist at AstraZeneca.

Andreas Pahl
CSO
Heidelberg Pharma

Professor Pahl has 20 years’ experience in research and teaching and excellent expertise in pharmacology, toxicology and pharmacokinetics. In 2008 he joined industry to pursue drug development for inflammatory and autoimmune diseases at Nycomed and Takeda.  In 2012 he joined Heidelberg Pharma as the CSO extending his expertise to the area of oncology and antibody-drug conjugates. Professor Pahl continues to be adjunct Professor for pharmacology and toxicology at the University of Erlangen-Nuremberg

Pre Conference Workshops Morning

Monday 20th February, 2017

10:00 | Workshop A: Exploring Novel Payloads & Their Differentiated Mechanisms of Action

Andrew Bessire
Scientist
Pfizer

Andrew Bessire is a Senior Scientist in the Medicinal Sciences Department at Pfizer.  Since joining the company in 1993, he has applied his experience in pharmacokinetics and drug metabolism to a variety of programs in both human and veterinary medicine.  His primary responsibilities include drug disposition and metabolite identification studies in both discovery and development.  He has been involved with ADC therapeutics since 2011.  

Christian Lanshoeft
Doctoral Candidate
Novartis & University of Strasbourg

Since 2015 Christian has started his PhD thesis, a joint collaboration between the University of Strasbourg (France) and Novartis Pharma AG Basel (Switzerland) under the supervision of Sarah Cianférani (PhD) and Olivier Heudi (PhD). His thesis focuses on “The use of mass spectrometric-based methods for the quantitative and qualitative analyses of hIgG-related therapeutic proteins in pre-clinical species” either at the peptide level using LC-MS/MS or directly at the intact protein level with hybrid LBA-LC-HRMS-based assays. In his last year as doctoral candidate, he will mainly focus on ADCs before defending his PhD in Dec 2017. Prior to his PhD thesis, Christian obtained the MSc (and also BSc) degree in Molecular Life Sciences from the University of Applied Sciences Northwestern Switzerland where he studied the “High-throughput quantitative analysis of small molecules in clinical samples using LDTD-APCI-MS/MS” under the supervision of Prof. Götz Schlotterbeck (PhD).

Christine Sedlik
Researcher
Institut Curie

Christine Sedlik is a Researcher at the Institut Curie in Paris. Christine received her PhD in 1996 from Universite Paris XI Orsay. Christine’s research focuses on the development of novel antibody drug conjugates.

Day Two

Wednesday 22nd February, 2017

16:00 | Effective Antitumor Therapy Based on a Novel Antibody-Drug Conjugate Targeting The Tn Carbohydrate Antigen

Cong Wei
Senior Scientist
Vertex Pharmaceuticals

Cong Wei is a Senior Scientist in the DMPK group at Vertex Pharmaceuticals. Prior to joining Vertex Cong held a position at Pfizer and Bristol-Myers Squibb. Cong has strong knowledge of analytical chemistry, drug metabolism, pharmacokinetics, pharmacology, biochemistry and cell and molecular biology.

Daniela Woide
Director
Project Pharmaceuticals

David Thurston
Professor
King’s College London

David Thurston is Professor of Drug Discovery in the Institute of Pharmaceutical Science at King’s College London.  He has a first degree in pharmacy and a PhD in synthetic medicinal chemistry.  David is one of the scientific co-founders of Spirogen Ltd (recently acquired by AstraZeneca), and acted as CSO for the company from its formation in 2000 until 2011.  He is also a co-founder of Transcriptogen Ltd, which focusses on the discovery and development of small-molecule transcription factor inhibitors as oncology agents, and Femtogenix Ltd which is involved with the discovery of novel DNA Minor Groove Binding Agents (MGBAs) with potential application as ADC payloads.  David has published widely in medicinal chemistry/chemistry journals, is author of the textbook “Chemistry and Pharmacology of Anticancer Drugs”, and Editor-in-Chief of the Drug Discovery book series of the Royal Society of Chemistry.  

Pre Conference Workshops Morning

Monday 20th February, 2017

10:00 | Workshop A: Exploring Novel Payloads & Their Differentiated Mechanisms of Action

Dominik Schumacher

Leibniz-Institute for Molecular Pharmacology

Pre Conference Workshops Afternoon

Monday 20th February, 2017

14:00 | Workshop D: Design & Develop More Stable Site-Specific ADC Linker Chemistries

Fabrizia Fusetti
Director Biologics Mass Spectrometry
QPS

Fabrizia Fusetti is group leader in the department of Bioanalysis at QPS Netherlands B.V.  Technological focus of her team is the development of bioanalytical mass spectrometry methodologies for the (regulated) determination and characterization of therapeutic proteins, monoclonal therapeutic antibodies, ADCs, peptides and oligonucleotides. She obtained her PhD in Biotechnology at the University of Milan (Italy) and before joining QPS she dedicated several years of her academic research at the University of Groningen (The Netherlands) to mass spectrometry based proteomics projects.

Francois D’Hooge
Head, Bioconjugation
Novasep

PhD in Rouen, France ( 2000-2004) on the synthesis of fluorinated glycopeptide to stabilise the protein-sugar bond. Then, a few  post docs including two years (2004-2006) at the University of Tokyo, doing total synthesis of a complex alkaloid, and two years at the University of Oxford ( 2008-2010), on a Bill and Melinda Gates fellowship for new radioactive imaging techniques for Mycobacterium Tuberculosis, where I started working on bioconjugation ( radioactive sugars on proteins) Joined Spirogen (London, UK) in 2011 to start its in house conjugation group, from 0 staff to 5 and turning over 1000 ADCs in 5 years. Joined Novasep in May 2016 to head its new bioconjugation facility in Le Mans

George Badescu
Scientific Director
Abzena

Giorgio Salciarini
Technical Business Development Manager
BSP Pharmaceuticals

Giorgio is part of the Business Unit,  with responsibility of coordinating Business Development activities He joined BSP Pharmaceuticals in 2008 as Manufacturing Manager than moved to BD in 2014. Prior to joining BSP Pharmaceuticals, Giorgio has achieved a significant experience in Manufacturing and Operation at Bristol Mayers-Suibb where developed his professional and technical growth. Giorgio holds a degree in Pharmaceutical Chemistry and Technologies from the University of Perugia.  

Heather Donaghy
Research Analyst for Beacon
Hanson Wade

Beacon ADC’s head analyst has been at Hanson Wade for almost 2 years now. Her role is to ensure that all relevant data on clinical stage ADCs is kept up to date on Beacon ADC, and as such is in a unique position to provide an impartial overview of the current pipeline. Heather has a immunology background, having completed her PhD at Imperial College, London and post doc in Sydney.

Day Two

Wednesday 22nd February, 2017

14:00 | Current Clinical Pipeline of Antibody Drug Conjugates

Jonas Helma
Ludwig-Maximilians
University of Munich

Pre Conference Workshops Afternoon

Monday 20th February, 2017

14:00 | Workshop D: Design & Develop More Stable Site-Specific ADC Linker Chemistries

Laurence Bonnafoux
Project Leader & Process Chemist
Lonza

Laurence Bonnafoux, Ph.D (born 1983) studied chemistry at École Européenne de Chimie, Polymères et Matériaux in Strasbourg (France). She obtained her PhD with Dr. Frédéric Leroux in collaboration with LONZA AG (Switzerland) at the University of Strasbourg in 2008 with a dissertation on the Modular Synthesis of Biaryl Ligands for Catalytic Hydrogenations and Coupling Reactions. Then, she went to ETH in Zürich (Switzerland) for a period of postdoctoral research under the direction of Professor Antonio Togni. In 2011 she joined LONZA AG (Visp, Switzerland) where she was in charge of the development and the scale-up of chemical processes for the production of pharmaceutical intermediates and APIs under cGMP. Since 2013 she has focused on the process development and transfer of early and late phase antibody drug conjugates processes.  

Lisa McDermott
Principal Scientist
Merck

I spent seventeen years with Monsanto working on both agricultural and pharmaceutical projects followed by seven years at Pfizer focused on analytical control strategies and transfer to manufacturing.  With over 25years of experience in both organic synthesis and analytical sciences, I have had the opportunity to contribute to many projects ranging from discovery to full development, but none have been exciting as the emergence of ADCs. I joined SAFC in January of 2010 as an Analytical Project Lead responsible for ADCs.  I also have an extensive chromatography background with experience in integrated LC/MS screening systems.  I am originally from the St Louis area and live on a small farm where we raise cattle and show pigs.

Day Two

Wednesday 22nd February, 2017

10:00 | Accelerated ADC Development with Integrated Supply Chain Solutions

Ludger Wessjohann
Managing Director
Leibniz Institute of Plant Biochemistry

Professor Wessjohann studied chemistry in Hamburg (Germany), Southampton (UK), and Oslo (Norway, Prof. Skattebøl). He earned his doctorate in 1990 with Prof. de Meijere in Hamburg. After a short period as lecturer in Brazil, he became a postdoctoral Feodor-Lynen fellow of the Alexander von Humboldt foundation with Prof. Paul Wender at Stanford University (USA) working on the total synthesis of Taxol®. After an assistant professorship in Munich (LMU, 1992-1998), he was appointed to the Chair of Bioorganic Chemistry at the Vrije Universiteit Amsterdam (NL), working on organometallic chemistry and biocatalysis. Since 2001, he is director of the dept. of bioorganic chemistry at the Leibniz Institute of Plant Biochemistry (IPB) in Halle (Germany), and in parallel holds the chair of natural product chemistry of the Martin Luther-University Halle-Wittenberg. In 2010, he was appointed the Managing Director (CEO/CSO) of the IPB (www.ipb-halle.de). Prof. Wessjohann focuses on the discovery, synthesis and application of natural products and bioactive derivatives thereof. He has over 300 publications, 25 patent applications, and is co-founder of five companies, two of which (www.ontochem.com and www.tubepharma.de) are active with drug conjugates for better targeting. He is member of many boards and commissions, and received numerous scholarships, prices and honors, e.g. the Microsoft IT Founders Award, State Innovation prize etc. He is honorary member of the Argentinean Soc. of Synth. Org. Chem. and a member of the Brazilian Academy of Sciences. In 2016, he won the “Leibniz Drug of the Year” award for Tubugis, anticancer peptides with low picomolar activity.

Pre Conference Workshops Morning

Monday 20th February, 2017

10:00 | Workshop A: Exploring Novel Payloads & Their Differentiated Mechanisms of Action

Martin Smyth
Process Development Consultant
Sartorius Stedium

Martin Smyth is a member of the Process Development Consultant (PDC) group at Sartorius-Stedim. Martin has a broad range of experience in the biologics field having worked for pharma (GSK), biotech (Pieris Pharmaceuticals) and CDMO (Cobra Biologics) spanning over 20 years. Martin received his PhD from Birkbeck College, London.

Milla Neffling
Advanced Workflow Specialist
Sciex

Nicole Giesen
Partner
Michalski Hüttermann Patent Attorneys

Nicole Giesen studied chemistry at RWTH Aachen with a focus on organic chemistry and polymer chemistry. She finished her PhD in enantioselective synthesis of allyl alcohols in 2001 at the same time as gaining a bachelor's degree in business administration. Nicole has worked in the IP field since 2002 and completed an internship lasting several months at the district patent litigation court in Düsseldorf in 2004. She has passed the German patent bar examination and has been admitted as a representative before the European Union Intellectual Property Office. Dr. Giesen is a founding partner of Michalski Hüttermann. Her main areas of practice are polymers, coatings, and pharmaceutics, overseeing both patent and trademark issues. She also has extensive experience in proceedings involving obtaining patents and utility models and in opinions. Her particular strengths lie in strategic advice, specialized patent research (e.g. freedom to operate and white-spot analyses) and on issues relating to patent evaluations and due diligence. "What I like most about my job is the wide variety and international nature of the issues and tasks that I handle." Dr. Giesen is a member of the Association of Intellectual Property Experts (VPP), the Federation of German Patent Attorneys, the Intellectual Federation of Intellectual Property Attorneys (FICPI), the Pharmaceutical Trade Marks Group (PTMG) and the International Trademark Association (INTA). Nicole Giesen was born in Aachen, Germany in 1970. She lived in Leeds, England from 2000 to 2002 and today calls Viersen, Germany home. She is married with two children. Outside the office, she likes to read English literature and go bike riding. Dr. Giesen is fluent in German and English.

Pre Conference Workshops Afternoon

Monday 20th February, 2017

14:00 | Workshop E: Intellectual Property Perspective on the Requirements for Successful ADC Drug Development

Norbert Sewald
Professor
University of Bielefeld

Pre Conference Workshops Morning

Monday 20th February, 2017

10:00 | Workshop A: Exploring Novel Payloads & Their Differentiated Mechanisms of Action

Omar Hamdy
Senior Scientis
Abbvie-Stemcentrx

Phil Howard
CSO
Spirogen

Dr Howard is a Founding Scientist and Chief Scientific Officer at Spirogen.  He has been conducting research into the pyrrolobenzodiazepine (PBD) family of antitumor antibiotics for twenty years in both academia and industry.  Philip has worked as a part of a multi-disciplinary team, supported by Cancer Research UK and Spirogen, on the synthesis, biological evaluation and development of the PBD dimers.  Since 2008 he has been working on the development of the PBDs as payloads for antibody-drug conjugate therapy with a number of leading companies including, Seattle Genetics, Stemcentrx, ADC Therapeutics, Genentech, Regeneron and Tanabe Research Laboratories USA Inc. Dr Howard designed the tesirine payload (SG3249) and the warhead SG3132 released by the talirine payload. His work at MedImmune is focused on the further development of their PBD-ADC platform.  At the time of writing, more than 12 PBD-ADCs, arising from Spirogen collaborations, are the subject of Phase I, Phase II, and Phase III clinical trials.

Robert Sussman
Managing Director
SafeBridge Consultants

Currently Managing Principal of SafeBridge Consultants’ Eastern Operations, Bob is a board certified toxicologist with 25 years’ experience in the pharmaceutical industry.  He has a degree in Engineering from Brown University and a Ph.D. in Environmental Health Science from NYU.  

Pre Conference Workshops Afternoon

Monday 20th February, 2017

14:00 | Workshop F: Safely Handle Highly Potent Payloads & Manufacture ADCS

Roberto Depaz
Senior Scientist
MedImmune

Roberto Depaz is a Scientist/engineer with extensive biomolecule formulation and process development experience. Experience encompasses a wide variety of molecule types: peptides, enzymes, fusion proteins, subunit protein vaccines, monoclonal antibodies, antibody-drug conjugates, viral vectors, and protein nanoparticles. Functional representative on Research Project Teams, CMC Teams, Regulatory filing support, and Due Diligence activities for partnering opportunities. Project support spans from preparation of preclinical toxicology supplies through Phase 3 clinical studies.

Pre Conference Workshops Morning

Monday 20th February, 2017

10:00 | Workshop C: Antibody Drug Conjugate Process Development & Formulation

Sonia Taktak
Development Scientist
ImmunoGen

Sonia Taktak is a Development Scientist in the Analytical and Pharmaceutical Sciences department at ImmunoGen, Inc. Sonia is responsible for providing analytical support to CMC activities for the manufacturing of antibody drug conjugates (ADCs) and their components (antibodies, linkers, and cytotoxic agents). Prior to Joining ImmunoGen, Inc. in 2013, Sonia worked as a bioanalytical development scientist at a CRO in the Boston area. Sonia holds a PhD in chemistry from Tufts University after which she completed her postdoctoral training as a Harvard Medical School fellow at Mass General Hospital (MGH) in Boston.

Sue Walker
Provantage® End-to-End Project Delivery
Merck

Sue Walker is currently on the Provantage End-to-End Solutions Delivery team at Merck.  Prior to her current position, she has over 25 years of technical experience touching on all major aspects of biopharmaceutical processing including R&D, Process Development, Clinical Manufacturing, Materials Management, Validation, and Quality Assurance as well as several years of Marketing experience.   Her experience has included both chemical and biological processing and over a decade of experience with single use technologies.   She earned her Master’s Degree in Chemical Engineering at Tufts University and a Bachelor’s Degree in Chemical Engineering from Worcester Polytechnic Institute.

Day Two

Wednesday 22nd February, 2017

10:00 | Accelerated ADC Development with Integrated Supply Chain Solutions

Ulrich Storz
Senior Partner
Michalski Huettermann Patent Attorneys

Pre Conference Workshops Afternoon

Monday 20th February, 2017

14:00 | Workshop E: Intellectual Property Perspective on the Requirements for Successful ADC Drug Development

Wen Jin Wu
Senior Investigator
FDA

Dr. Wen Jin Wu is currently a Senior Investigator in Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA. He earned his M.D. from Wannan Medical College, China and his Ph.D. at Cornell University in 2002. He was recruited as a Principal Investigator (PI) in Division of Monoclonal Antibodies in 2004. In addition to his regulatory duty as a product quality reviewer, Dr. Wu’s laboratory focuses on understanding the roles of ERBB family receptors in breast cancer progression and the mechanisms of trastuzumab resistance, and trastuzumab and T-DM1-induced toxicity. He has published a number of papers in highly reputed journals, including Journal of Biological Chemistry, Nature, Cell, Molecular Cancer Therapeutics, and Cancer Research, and has been invited to give talks in a number of national and international conferences.

Day One

Tuesday 21st February, 2017

17:45 | Regulatory Considerations & Case Studies for Antibody-Drug Conjugates

Yannis-Nicolas Francois
Assistant Professor
University of Strasbourg

Y.-N Francois completed a PhD in Analytical Chemistry at the University of Pierre et Marie Curie in Paris (2006). He then went to University Paris Descartes as a Post-doc (2006-2007). Since 2007, he has held a permanent position of Assistant Professor at University of Strasbourg.  He is current research involves studying intact proteins and non-covalent complexes using CE-ESI-MS and CE-MALDI-MS.

Alain Beck
Senior Director, Physio-Chemistry
Pierre Fabre

Dr. A. Beck is Senior Director, Antibody/ADC Physico-Chemistry and member of the board of directors of the CIPF. He contributed to the R&D of anticancer mAbs (dalotuzumab/IGF-1R with Merck, h224G11-ABT700/cMet with Abbvie, h515H7/CXCR4, h6F4/JAM-A), vaccines and peptides (AUPN12/ PD-1 decoy with Aurigene). He is inventor on 16 patents, author of near 130 publications and reports, associate editor of mAbs (www.landesbioscience.com) and guest editor for special issues on mAbs (Nat Rev Immunol, Curr Pharm Biotech, Medecine/ Sciences and Meth Mol Biol). He has contributed to more than 200 scientific communications in meetings as chairman, invited speaker, panellist, moderator, advisor, and/or organizer. He is also regularly invited to boards of experts by the WHO, the EMA, the European Commission, the EDQM, Funding Agencies (Belgium, Czech, Dutch, France, Ontario, Poland, New Zealand) and bio-clusters (Alsace Biovalley, CLARA, Genopole, LyonBiopole).

Day One

Tuesday 21st February, 2017

18:15 | Chair’s Closing Remarks

16:30 | Cutting-Edge Analytical & Structural Methods for Characterisation of ADCs

08:50 | Chair’s Opening Remarks

Day Two

Wednesday 22nd February, 2017

16:30 | Chair’s Closing Remarks

08:50 | Chair’s Opening Remarks

Anette Sommer
Principal Scientist
Bayer AG

Anette Sommer is a Principal Scientist in Oncology Research at Bayer AG, Berlin, Germany. She studied biochemistry at the Universities of Hannover, Germany and Glasgow, United Kingdom and got her diploma degree in Biochemistry in 1994 from the University of Hannover. She obtained her doctoral degree in 1997 from the Medical School Hannover (MHH), Germany. During her PhD she focused on the Myc-Max-Mad network of transcription factors and chromatin modulation. After a PostDoc at the Institute for Molecular Biology, Anette Sommer joined Schering Pharma AG in Berlin at the Department of Experimental Oncology. She then continued at the Department of Enabling Technologies and was involved in target Identification and target validation for various indications. Since 2007 she is with Bayer Pharma AG and has been involved in inlicensing of target candidates, the Grants for Targets (G4T) Initiative, and various collaborative projects, e.g. with DKFZ, Heidelberg and Tsinghua University, Beijing and Cancer Research UK (CRUK). Her current focus are antibody-drug conjugates for cancer therapy.

Arnaud Delobel
Scientific Manager, Biologics
Quality Assistance

Arnaud Delobel is the Scientific Manager of Biologics at Quality Assistance. Arnaud acts as the hub for the management of biological products (proteins, antibodies and derivatives) in Quality Assistance. He identifies market needs with input from the Management, Regulatory Affairs Manager and external experts, and from any relevant data gathered by Quality Assistance. Olivier is responsible for interpreting and translating  this intelligence into to developing new R&D services.

Chakrapani Subramanyam
Associate Research Fellow
Pfizer

Chakrapani Subramanyam is an Associate Research Fellow in the Global Research & Development department at Pfizer. Subbu has been at Pfizer for the last 20 years. He received his education at Penn State University.

Charles Dumontet
Team Leader
Cancer Research Centre Lyon

Charles Dumontet is a Team Leader at the Cancer Research Center Lyon. His group studied the mechanisms of action of monoclonal antibodies that are targeting cancer cells. We also study the mechanism of resistance towards these biomolecules in order to increase the activity of therapies based on monoclonal antibodies in patients with hematological malignancies or solid tumors.

Christoph Rader
Associate Professor, Cancer Biology
The Scripps Research Institute

Dr. Christoph Rader has been an Associate Professor with tenure at The Scripps Research Institute in Jupiter, Florida (TSRI-FL) since 2012 and currently also serves as Acting Associate Dean of Graduate Studies. Dr. Rader joined TSRI-FL after 9 years as the Head of an Antibody Technology Section at the National Cancer Institute, National Institutes of Health (NIH) in Bethesda, Maryland.  Prior to this position, Dr. Rader was Assistant Professor at The Scripps Research Institute in La Jolla, California (TSRI-CA) from 1999 to 2003.  He was a postdoc in the laboratory of Dr. Carlos F. Barbas III at TSRI-CA from 1996 to 1999 after graduating with a Ph.D. in biochemistry and molecular biology from the University of Zurich in Zurich, Switzerland.  Dr. Rader is a leading scientist in antibody drug and target discovery for cancer therapy.  He has authored >100 journal articles and book chapters, is named inventor on >25 issued and pending patent applications, and lectures frequently.  Antibodies developed in Dr. Rader’s NIH-funded laboratories at TSRI-CA, NIH, and TSRI-FL have been licensed to companies and translated to clinical trials.  A particular focus of Dr. Rader’s TSRI-FL laboratory is devoted to antibody technologies at the interface of biology and chemistry, including the generation of site-specific antibody-drug conjugates and chemically programmed antibodies.  In addition to his academic activities, Dr. Rader serves on the Scientific Advisory Boards of NBE-Therapeutics, Inc. (Basel, Switzerland) and BlinkBio, Inc. (Jupiter, FL).

Damon Meyer
Associate Director
Seattle Genetics

Damon Meyer received his Bachelor’s degree in Chemistry from Pomona College, and his Ph.D. from the University of California at Davis.  Working first at Hybritech, Inc. then NeoRx Corp., he developed antibody-enzyme conjugates and antibody-streptavidin conjugates for the delivery of oncolytics and radionuclides to tumors.  Joining Seattle Genetics in 2000, Dr. Meyer worked on antibody-drug conjugates for preclinical studies, studied the affinity of auristatins for tubulin, and the relationship between affinity and cytotoxicity.  Dr. Meyer helped develop the commercial conjugation manufacturing process for Adcetris and the Phase I clinical conjugation process for an anti-CD33-pyrrolobenzodiazepine dimer engineered-cysteine ADC.  

David Satijn
Director, New Antibody Products
Genmab

David Satijn holds a PhD in Molecular Biology from the University of Amsterdam. He was a Post-Doctoral Research Fellow at the department of Immunology, University of California San Diego where he studied T and B cell development. He became an Assistant Professor at the University of Amsterdam where he worked on the role of epigenetic elements and the stable production of recombinant antibodies. In 2006, he joined Genmab and is currently supervising Target Discovery, Antibody drug conjugate (ADC) technologies and Antibody Discovery Programs. David Satijn is based in Genmab Utrecht, the Netherlands and serves in the position Director, New Antibody Products.

Day Two

Wednesday 22nd February, 2017

15:30 | Elimination of Multidrug-Resistant Melanoma by HuMax-AXL MMAE

Dhaval Shah
Assistant Professor
University of Buffalo

Dr. Dhaval K. Shah is an Assistant Professor in the Department of Pharmaceutical Sciences at the State University of New York at Buffalo. His research focuses on understanding the determinants for the pharmacokinetics (PK) and pharmacodynamics (PD) of ADCs. His lab uses the principles of PK/PD Modeling & Simulation to support discovery and clinical translation of novel ADCs. Some current research projects is lab include: quantifying bystander effect of ADCs, understanding the determinants for the elimination of high DAR ADCs, evaluating the effect of antigen expression on intracellular ADC PK, and development of a platform PBPK model for ADCs.

Day Two

Wednesday 22nd February, 2017

14:30 | Quantitative Characterization of the Bystander Effect of ADCs

Donglu Zhang
Principal Scientist
Genentech

Pre Conference Workshops Morning

Monday 20th February, 2017

10:00 | Workshop B: Clinical ADC Development: Maximise the Clinical Therapeutic Window

Gary Chen
President
Concortis Biotherapeutics

Gang Chen is president of Concortis Biotherapeutics since March 2016.  Dr. Chen was VP, ADC technology at Concortis Biosystems from 2013 to 2016.  He was instrumental in developing Concortis’ conjugation methods and ADC programs.  Prior to join Concortis Biosystems, he worked at Pfizer, Quidel, Diversa and Diazyme.  Dr Chen obtained BS in physical chemistry from Beijing University of Chemical Technology, and PH. D in biochemistry from The University of Texas at Austin.

Day Two

Wednesday 22nd February, 2017

09:00 | Preclinical Development of Superior ADCs Incorporating Novel Linker & Warhead Designs

Guodong Chen
Senior Principal Scientist
Bristol-Myers Squibb

Dr. Guodong Chen has extensive pharmaceutical research experience in major pharmaceutical companies, including Eli Lilly and Company, Schering-Plough and Bristol-Myers Squibb. Currently, he heads analytical/mass spectrometry group at BMS Princeton site, providing analytical/mass spectrometric support to drug discovery programs and development projects in small molecule pharmaceuticals, biologics and ADCs. His matrix team leadership includes program leader. He has over 75 research publications in peer-reviewed journals and book chapters, over 100 presentations, multiple patents on antibody therapeutics and three edited/co-edited books in pharmaceutical analysis. His scientific contributions include short course instructor at conferences, invited reviewer for journals, and invited speaker at national/international conferences and academic institutes. He also organized/chaired scientific sessions at various forums. He received his Ph.D. in Analytical Chemistry from Purdue University under the direction of Professor R. Graham Cooks.

Iontcho Vlahov
Vice President, Discovery Chemistry
Endocyte

Dr. Vlahov received his PhD in synthetic organic and structural chemistry from Ruhr University, Bochum, Germany. Before joining Endocyte, he was the head of discovery chemistry at Ivax Corp in Miami, Florida. Prior to that, he held various positions, including visiting scientist at Hercules, Inc.; senior research scientist at the University of Konstanz, Germany; research scientist at the Institute of Organic Chemistry, Bulgarian Academy of Sciences; and research associate at the University of Iowa. Dr. Vlahov’s main scientific interest is the design and synthesis of complex biologically active molecules.  In the past 18 years, as the head of Endocyte’s Discovery Chemistry department, Dr. Vlahov has been active in the discovery of personalized targeted therapies of cancer and autoimmune diseases.  His research efforts are aimed toward discovery of novel small molecule drug conjugates, linker systems, spacer units, and highly potent warheads. To date, these programs led to the development of seven clinically investigated agents.  Dr. Vlahov is an Alexander von Humboldt Fellow and recipient of George and Christine Sosnovsky Award for Cancer Research.

Joachim Krueger
Head of Process Development
Bayer

  • Study of Chemistry at the Technische Universität München and the Philipps-Universität Marburg (Diploma, PhD); supervisor Prof. R.W. Hoffmann
  • Postdoctoral fellow at the California Institute of Technology, Pasadena; supervisor Prof. E. Carreira
  • Laboratory head in medicinal chemistry at Bayer Pharma
  • Laboratory head and Principal Scientist in Chemical Development, Bayer Pharma, Wuppertal
  • At present: Director of Process Chemistry: Head of Process Research & Development unit within Chemical Development, Bayer Pharma.

John Lambert
Executive Vice-President & Distinguished Research Fellow
ImmunoGen

John Lambert joined ImmunoGen in 1987. Prior to this, he was an Assistant Professor at Harvard Medical School. Dr. Lambert holds a Ph.D. in Biochemistry from the University of Cambridge.

Day One

Tuesday 21st February, 2017

09:00 | Preclinical & Translation of IMGN632 & Clinical Update of Mirvetuximab Soravtansine

Judy Hsii
Senior Engineer & Group Leader
Genentech

Judy Hsii is a Process Development Engineer at Genentech with 12+ years of biotech industry experience. Judy is highly proficient in protein purification and antibody drug conjugation (ADC) process development in both CHO and E.coli derived systems from development to characterization and validation through commercialization. She is experienced in technology transfers to network sites as well as international CMOs (Europe and new CMO in Asia).

Kurt Gish
Associate Director II, Biologics Technologies
AbbVie

Kurt Gish, Ph.D. leads the ADC Discovery Group at AbbVie’s site in Redwood City, California. Through multiple corporate spin-outs and acquisitions, this is his sixth company, but still his first job, and for the past 20 years has worked on antibody-drug conjugate (ADC) target selection and drug development at Affymetrix, Eos Biotechnology, PDL BioPharma, Facet Biotech, Abbott Labs, and now AbbVie. His research group specializes in the discovery, design, and pre-clinical development of ADCs, and works closely with his colleagues at all of AbbVie’s R&D sites to improve ADCs through protein engineering, linker chemistry, and novel mechanism-of-action payloads. He received his Ph.D. in Biological Sciences in 1994 from Stanford University in the laboratory of Charley Yanofsky, and did post-doctoral work at DNAX (now Merck Research Laboratories, Palo Alto). Kurt is an inventor on more than 20 issued U.S. patents, and an author on more than a dozen peer-reviewed publications, focused on cancer-specific antigens and their use for treating cancer.

Day One

Tuesday 21st February, 2017

17:15 | Preclinical Evaluation Of ABBV-838, A First-In-Class Anti-CS1 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma

Ling Xu
Senior Scientist
Takeda

Ling Xu is a PhD trained in enzymology with 15 years of experience in quantification and characterization of both small and large molecules in industry and academia. Ling  has a proven track record of scientific accomplishments and problem-solving skills.

Martin Mattarella
Head of Chemistry
Philochem

Martin Mattarella studied chemistry at the Universita’ degli Studi di Milano, Italy, where he performed his diploma thesis in 2010. On the same year he joined the group of Prof. Jay Siegel at the University of Zurich, Switzerland, where he worked in the field of physical organic chemistry; for this work Martin Mattarella was awarded a PhD degree at the end of 2013. After a 1 year postdoc in the group of Prof. Hiroyuki Isobe at the Tohoku University, Japan, working on artificial siRNA, Martin Mattarella joined Philochem AG where he is responsible for the development of novel targeted cytotoxics and DNA encoded chemical library technology

Miro Eigemann
Researcher, Pharmacokinetics Department
Roche

  • Graduated with a master degree in biomedical sciences from the University of Bern (CSL Behring award)
  • Currently Dr. cand. Phil. in the Pharmacokinetics department at Hoffmann-La Roche in Basel (Switzerland) and the University of Bergen (Norway)
  • Research focus: Investigation of effect driving concentrations at the target side using a combination of in vivo experimentation and mathematical modeling approaches with a strong focus on the biodistribution and tissue uptake of therapeutic proteins.

Olivier Heudi
Laboratory Head, DMPK
Novartis

Olivier Heudi obtained his diploma of advanced studies in physiology and pharmacology at Pasteur Institute Paris (France) in 1995 and his Ph.D. in life Sciences at the University of Angers France in 1999. He previously gained experience in the analytical field at GSK Stevenage (UK) where he has implemented LC-ICPMS and LC-MS/MS for the quantification of peptide in biological fluids and at Nestlé Lausanne (CH) where he developed LC-MS/MS methods for the identification and quantification of vitamins and natural ingredients in food products and in raw materials. Then he joined Novartis Institute for Tropical Diseases (Singapore) where he was leading the bioanalytical laboratory. In December 2006, Olivier was appointed as laboratory head in the DMPK group where he is now working on LC-MS/MS method development and implementation for the quantification of monoclonal antibodies, oligonucleotides and small molecules in

Olivier Marcq
Group Lead, ADC Development & Manufacturing
Agensys

Olivier Marcq is the Group Leader of Development & Manufacturing at Agensys, an affiliate of Astellas Pharma. Olivier is an expert in bioconjugation applied to biotherapeutics. His pharmaceutical industry experience encompasses discovery/research, early phase development and process development.  

Robert Kolakowski
Senior Scientist, Chemistry
Seattle Genetics

Robert Kolakowski is a Senior Scientist in the Chemistry Team at Seattle Genetics. Robert specialises in synthesize chemotypes (payloads), development of linker technology for attachment of payloads to antibody drug conjugates (ADCs), and advancing alternative ADC modalities.

Robert Xin
Executive Director & Global Clinical Lead, Oncology
Early Clinical Development, Pfizer

Physician-Scientist, Executive Director and Global Clinical Lead in Oncology Early Clinical Development at Pfizer.

Ron Lin
Founder & CEO
AbGenomics

Dr. Lin is founder and CEO of AbGenomics International Inc. (2006 – now). He founded AbGenomics Corp. and served as CEO from 2000 to 2006. To efficiently collaborate with top talents and key opinion leaders in both inflammation and cancer fields, the company relocated the headquarters to San Francisco Bay Area. He is the key inventor of 13 granted and 13 pending worldwide patents. Under his leadership and well established collaborative culture, the company discovered 6 promising new therapeutic candidates and has filed 5 INDs and completed 4 clinical trials successfully. The lead compound his team discovered has demonstrated significant clinical proof of efficacy in 3 different diseases. Prior to joining AbGenomics, Dr. Lin was founding Professor and Director of Graduate Institute of Immunology, College of Medicine, National Taiwan University (1991 – 2000). He received his “Diplom” Degree in Biotechnology, Summa Cum Laude, and Doctor Degree in Immunology, Magna Cum Laude, from the University of Tübingen in Germany. He has conducted his research works in Max Planck Institute for Immunogenetics in Germany (with Dr. Jan Klein, 1984-1987), Basel Institute for Immunology in Switzerland (1987-1989), and Immunobiology Division at Howard Hughes Medical Institute at Yale University (with Dr. Charles Janeway, 1989-1991).  

Day Two

Wednesday 22nd February, 2017

09:30 | AbGn-107, an ADC Targets Gastrointestinal Tumours

Sophia Hober
Professor, School of Biotechnology, Division of Proteomics
KTH

Sophia Hober is Professor of Molecular Biotechnology at KTH, Stockholm, Sweden. Between 2003 and 2011 she was part of the executive management team of Human Protein Atlas and from 2011 to 2015 part of the executive management team at KTH. She has published more than 100 scientific papers and supervised 16 PhD-students to their dissertation. The focus of her current research group is protein production, purification and characterization. Her group develops predictable and robust systems for protein purification and detection through protein design and various selection methodologies. Her key scientific achievements include design and development of gene fusion systems for selective ion-exchange purification and improvements of the alkaline tolerance of protein A for industrial purification of IgG (currently a product sold by GE Healthcare). Recently her group has developed a small bispecific protein domain to be used in cancer

Steve Coats
Vice President, External Science Strategy
MedImmune

Steve Coats is currently the Vice President of External Science Strategy at MedImmune. Steve received his Post Doc from Fred Hutchinson Cancer Research Canter in Seattle. He then went on to work for Amgen before arriving at MedImmune where he has been intrinsically involved with oncology research for the last 12 years.

Daryl Drummond
Senior Director of Nanotherapeutics
Merrimack Pharmaceuticals

Dr. Drummond currently serves as the Senior Director of Nanotherapeutics for Merrimack Pharmaceuticals, leads the nanotechnology efforts at Merrimack and was one of the principle inventors for many of Merrimack's nanotechnology-based drugs and platform technologies. MM-398, a nanoliposomal formulation of irinotecan is currently in Phase III clinical trials and MM-302, and ErbB2-targeted pegylated liposomal doxorubicin is currently in Phase I trials in metastatic breast cancer.  At Merrimack he leads a broad multidisciplinary team of chemists, biologists, pharmacologists, and biophysicists.  Daryl joined Merrimack in October of 2009 following the merger of Merrimack with Hermes Biosciences.  Dr. Drummond received a Ph.D. degree in Biochemistry from Indiana University in 1997, with an emphasis on membrane biochemistry and biophysics.   He later joined Hermes Biosciences in 2000 as an Associate Director of Liposomal Research and Development following a post-doc in the laboratory of the renowned father of current liposome drug delivery systems, Demetrios Papahadjopoulos.  Overall, Dr. Drummond has more than 20 years of experience in the research and development of advanced drug delivery systems, including four unique drugs that have been tested in various clinical trials, eight issued patents or patent applications, and more than 50 peer reviewed publications focused on lipid-based nanotherapeutics.  

Tok Han
Director/TL, Oncology Operations
Pfizer

Tok Han is the Director and Team Leader of Oncology Operations at Pfizer. Tok is responsible for disposable technologies and has been working with these technologies since 2000. He is intrinsically involved in the manufacturing of inotuzumab ozogamicin

Tony Cano
Senior Director, Process Sciences
Stemcentrx-AbbVie

Tony Cano received his B.E. in Chemical Engineering cum laude from Vanderbilt University in 1999, and his Ph.D. in Chemical Engineering from University of Houston in 2004. Following graduate school Tony joined Genentech where he was involved in the process development, technology transfer and validation of several clinical and commercial biopharmaceutical processes.  While at Genentech Tony also played a key role in the development of modern risk-based approaches for validation of biopharmaceutical processes.  Tony joined Stemcentrx in 2013 and is currently Director of Process Sciences where he oversees cell culture, purification, conjugation, analytical and formulation development groups.

Wayne Widdison
Associate Director of Chemistry
ImmunoGen

Wayne is the associate director of chemistry at ImmunoGen. He joined the company in 1993, and his group is focused on the design of maytansinoid ADCs that efficiently release one or more potent metabolites for the treatment of solid or liquid tumors.  Today he will be talking about peptide linked ADCs that release mono-charged metabolites and comparing them to non-cleavably linked ADCs

Yves Baudat
Scientist
Sanofi

Graduated with a French equivalent to MSc. After ~3 years working on HIV in an academic lab, I started in industry in 1998 and in oncology since 2000. Background in molecular biology, cell biology, virology, target validation and leading of preclinical research teams. Joined the Sanofi’s group dedicated to ADC in 2010, since then team leader of several projects, from target Id/validation to development candidate.  Currently in charge of 2 early projects with DNA binder payload.

Pernille Hemmingsen
Project Manager, CMC
Genmab

Pernille Hemmingsen has more than decade of experience within development of pharmaceutical products within both solid and liquid dosage forms. With a background in biophysical chemistry and chemical engineering, development of stable products and robust manufacturing methods has had her particular interest. This interest had led to development of products within cancer targeting liposomes, tamper resistant tablets and enhanced diabetes formulations. Currently, Pernille Hemmingsen holds responsibility for the chemistry manufacturing and control of the HuMax-TF-ADC antibody-drug conjugate program. Particularly, this work includes establishing an efficient supply chain that encompasses elements from both small molecules and biologics. Pernille holds a Ph.D. from Department of Chemistry at the Technical University of Denmark and a Master of business administration from Copenhagen Business School.  

Puja Sapra
Vice President and Chief Scientific Officer
Pfizer

Puja Sapra is Executive Director at the Oncology Research Unit, Pfizer where she oversees preclinical development of all antibody drug conjugate therapeutic programs. Prior to joining Pfizer, she led Pharmacology groups at Enzon Pharmaceuticals and Immunomedics Inc. and developed oncology-based drugs that are undergoing clinical evaluation. Puja Sapra received a Bachelors degree from All India Institute of Medical Sciences, an MS in Pharmacology from UK and a PhD in Pharmacology from University of Alberta, Canada. Since PhD she has developed various therapeutic modalities including antibodies, antibody-drug conjugates, pegylated drugs, nanoparticles and antisense oligonucleotides.   She is an author of >50 scientific publications, book chapters and co-inventor on several issued patents.

Day One

Tuesday 21st February, 2017

09:30 | The Next ADC Breakthrough Therapy – A Case Study of Inotuzumab Ozogamicin

Ulf Grawunder
CEO & Founder
NBE Therapeutics

Ulf Grawunder is founder and CEO of NBE-Therapeutics, a new Swiss Biotech company that was created in April 2012, and which focuses on the development of "next-generation" antibody-drug conjugates for cancer therapy. Prior to that, Ulf Grawunder had co-founded 4-Antibody Ltd in 2004, a Swiss therapeutic antibody engineering company, where he initially served as CEO and since 2006 as CSO. Ulf Grawunder obtained his PhD from University of Basel for work performed at the Basel Institute for Immunology. After his PhD he did several years of post-doctoral research at Washington University School of Medicine, St. Louis, and the University of Southern California, Los Angeles in the U.S. After this he returned to Europe and held positions as principal investigator at the Basel Institute for Immunology, the University of Ulm, Germany, and the University of Basel, Switzerland, before starting his first biotech company. Ulf Grawunder is member of a number of national and international boards of for profit and non-profit organizations, including the scientific advisory board of the Bavarian Immunotherapies Network, BayImmuNet, Germany (www.bayimmunet.de), and the Board of the Swiss Biotech Association (SBA, www.swissbiotech.org).